Główne pojęcia
Active surveillance is preferred over immediate treatment for low-risk prostate cancer patients, showing comparable outcomes.
Statystyki
Overall, 83% (706 of 852) men chose active surveillance over immediate treatment.
Patients aged 75 years or older were more likely to choose active surveillance (odds ratio [OR], 4.27).
Patients with a Charlson Comorbidity Index ≥2 were more likely to choose active surveillance (OR, 1.98).
Patients who underwent independent revision of the first biopsy were more likely to choose active surveillance (OR, 2.35).
Patients who underwent multidisciplinary assessment were more likely to choose active surveillance (OR, 2.65).
Patients with worse prognostic factors like stage T2a (OR, 0.54) and Gleason Score 3+4 (OR, 0.20) were less likely to choose active surveillance.
Cytaty
"The main remarkable finding of [the trial] is represented by the widespread adoption of active surveillance in our [Regional Oncology Network] since the beginning of the study, and the increasing trend over time, reaching approximately 90% of eligible patients in 2020 to 2021." - Authors